PIK3CA and breast cancer: PFS analysis using the Kaplan–Meier method and log-rank test demonstrated that metastatic BC patients harboring PIK3CA mutations had significantly shorter PFS than those without (median, 7 months; 95% CI, 5.0–9.0 vs. 15 months; 95% CI, 7.35–22.64; p = 0.022).